Vivek Ramaswamy is a self-styled social justice in the boardroom, fueling his battle with what he calls “Woke, Inc” with television appearances, opinion pieces, and two books. books and public letters to S&P 500 companies.
Now he is putting other people’s money in his mouth. Since August, the serial entrepreneur has launched two new exchange-traded funds that apparently seek to pressure companies to abandon efforts to diversify their workforce and rescind their commitment to tackling change. climate.
Strive, his new operations asset manager, has just raised just over $300 million in assets, mostly from retail investors, and it recently hired two former State Street executives to run it. run sales organizations.
The move comes amid growing backlash against asset managers, who use environmental, social and governance factors to influence their investments. . Conservative politicians in more than a dozen US states are threatening to pull state investments away from BlackRock and other asset managers they trust. say “boycott” fossil fuels or else too advanced.
“There is an opportunity to build the biggest asset manager in the world,” the 37-year-old told the Financial Times. “For me, however, the personally motivating goal is to realize our mission to be the voice for everyday citizens, representing an exclusive focus on excellence in the boardroom. of the company.”
This is not the first time Ramaswamy has raised money through bold claims. He launched two giant biotech floats when that field was booming in the 2010s, including one that was valued at almost $3 billion even though it contained only one unproven drug. .
Strive ETFs are established as passive index trackers seeking to compete directly with industry leaders BlackRock, State Street and Vanguard. STRV, which holds all the companies in the S&P 500, has an expense base ratio of 5.45, more than twice as much as Vanguard for a similar product, but lower than market leader State. Street. DRLL tracks the US energy stock index, and its 41bp premium is four times that of State Street, but roughly the same as BlackRock.
Ramaswamy last week wrote a public letter to Apple ask it to stop its racial justice audit plans and Disney stressed that the company stopped “speaking out on political issues that don’t affect its business,” such as gay rights. He also said he recently met with Chevron’s chief financial officer to express his belief that oil companies with no business are trying to reduce the carbon footprint of their suppliers and customers. surname.
“It’s like McDonald’s volunteering to take responsibility for the adult body weight of anyone who eats a Big Mac,” he said, during a meal where he ordered five different Mexican dishes, taking a few bites each. and leave out the rest.
Strive’s marketing materials say that if oil and gas companies are freed from the climate and other ESG concerns, “US energy stocks are likely to appreciate two to three times more in the 12-month period.” next 24 months”.
Conventional energy economists and analysts say it’s highly unlikely that ExxonMobil and Chevron, which hold a 38% stake in DRLL, will judge that quickly. Historically, shares of energy companies have followed a similar trajectory to oil prices, briefly soaring to $130 a barrel after Russia invaded Ukraine and falling to $85.
The expectation that the overall DRLL ETF “will double makes me too ambitious,” said Pavel Molchanov, energy analyst at Raymond James. “This will trade in tandem with the price of oil.”
Ramaswamy said Strive evaluates companies differently. He argues that energy companies trade at a lower price-to-earnings ratio than the broader market because investors believe fossil fuels will stop being used after 2030. With the absence of climate-related restrictions, he said, investors would appreciate the long-term value of output more.
“The price that investors are willing to pay for those returns will go up,” he said. “The ESG movement has offered a price to multiple compression earnings.”
Ramaswamy can point to a record of attracting large supporters. In 2014, he founded Roivant Sciences (called “return on investment”), which applies technology to drug development through a series of subsidiaries the company calls “vants”. The company received a 2017 infusion from SoftBank’s Vision Fund.
A subsidiary, Axovant, emerged in 2015 with just one drug in its portfolio, an Alzheimer’s drug that GSK sold for $5 million. It raised $315 million and was valued at nearly $3 billion after its first day of trading, making it the largest initial public offering ever. Medicine failure in late-stage testing in 2017. Today, the company, now known as Sio Gene, is valued at $22 million.
Myovant, the biggest biotech IPO of 2016, fared better. The two drugs it bought from Takeda have been approved by the FDA. The company is valued at $1.6 billion, even though the stock is down nearly 40% from its 2020 peak.
While running Roivant, Ramaswamy signed a contract in 2017 open letter in which biotech CEOs outlined best practices for increasing diversity. The executives wrote: “Unconscious biases are ubiquitous and difficult to identify and address. . . We agree with the importance of setting specific recruitment goals for achieving gender equality and inclusion at each level of our organization, and regularly measuring and reporting on progress. our targets. “
By the time he was already the author Woke, Incbecame a New York Times bestseller, in 2021 he changed his tune, writing: “When organizations combine indicators of racial and gender diversity with intellectual diversity, ideas in their organization, they implicitly reinforce the incorrect assumption that genetic traits predict something important about the way a person thinks. ”
Roivant went public last October by merging with a special-purpose acquisition vehicle in a deal that came months after Ramaswamy stepped down from his role as CEO and became chairman. Shares have fallen nearly 70% since the merger, pushing the company’s value down $2 billion.
“Drug development includes successes and failures, and we shared both. At the end of the day, I believe in judging based on the results of the impact we have,” he said. “I started a company with four people in a side room over dinner, and it’s a multi-billion dollar company that has five FDA-approved drugs. “
Ramaswamy is also the co-founder of Chapter, a for-profit technology platform that advises seniors on Medicare. It raised $42 million in January and has backing from Peter Thiel, the venture capitalist who has financed populist US Senate candidates.
When Ramaswamy stepped down from Roivant’s day-to-day management position, he toyed with the idea of running to become a Senator of Ohio, where he grew up and where Strive is based. He is a significant donor to the Republican Party, having given more than $80,000 to the party and its candidates since 2014.
But instead, he chose to start Striving. “The issues I care about are best solved through markets rather than state action,” he said.